Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones

PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · see citing works

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · see citing works

Diabetes mellitus and the risk of dementia: The Rotterdam Study

Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175 · see citing works

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · see citing works

Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes?

Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · see citing works

Pathology of Neurodegenerative Diseases

Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665 · see citing works

Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function

Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · see citing works

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment: A Pilot Clinical Trial

Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253 · see citing works

Alzheimer’s disease is type 3 diabetes—Evidence reviewed

de la Monte, S. M., & Wands, J. R. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200619 · Cited by 1,158 · see citing works

Metformin as a tool to target aging

Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096 · see citing works

Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice

Palacino, J. J., Sagi, D., Goldberg, M. S., Krauss, S., Motz, C., Wacker, M., Klose, J., & Shen, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401135200 · Cited by 995 · see citing works

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling

Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · see citing works

Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease

Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748 · see citing works

Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: Link to brain reductions in acetylcholine

Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · see citing works

α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress

Hsu, L. J., Sagara, Y., Arroyo, A., Rockenstein, E. M., Sisk, A., Mallory, M. E., Wong, J., Takenouchi, T., Hashimoto, M., & Masliah, E. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64553-1 · Cited by 716 · see citing works

Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

Hanson, L. R., & Frey, W. H. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-s3-s5 · Cited by 700 · see citing works

Insulin Action in Brain Regulates Systemic Metabolism and Brain Function

Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 688 · see citing works

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease

Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686 · see citing works

Insulin Resistance and Alzheimer-like Reductions in Regional Cerebral Glucose Metabolism for Cognitively Normal Adults With Prediabetes or Early Type 2 Diabetes

Baker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639 · see citing works

Brain Insulin Resistance at the Crossroads of Metabolic and Cognitive Disorders in Humans

Kullmann, S., Heni, M., Hallschmid, M., Fritsche, A., Preissl, H. T., & Häring, H. (2016) · Physiological Reviews · doi:10.1152/physrev.00032.2015 · Cited by 632 · see citing works

Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications

Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622 · see citing works

Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype

Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., Belongia, D., Fishel, M. A., Plymate, S. R., Schellenberg, G. D., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.016 · Cited by 619 · see citing works

Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone

Watson, G. S., Cholerton, B. A., Reger, M. A., Baker, L. D., Plymate, S. R., Asthana, S., Fishel, M. A., Kulstad, J. J., Green, P. S., Cook, D. G., et al. (2005) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.13.11.950 · Cited by 607 · see citing works

Memory improvement following induced hyperinsulinemia in Alzheimer’s disease

Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., & Alderson, A. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02002-0 · Cited by 538 · see citing works

Brain Atrophy in Type 2 Diabetes

Moran, C., Phan, T. G., Chen, J., Blizzard, L., Beare, R. J., Venn, A., Münch, G. W., WOOD, A. G., Forbes, J. M., Greenaway, T. M., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0143 · Cited by 521 · see citing works

Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease

Simpson, I. A., Chundu, K. R., Davies‐Hill, T., Honer, W. G., & Davies, P. (1994) · Annals of Neurology · doi:10.1002/ana.410350507 · Cited by 490 · see citing works

Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease

Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467 · see citing works

Long-Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzheimer's Disease Dementia

Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141791 · Cited by 467 · see citing works

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis

Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455 · see citing works

Insulin signaling meets mitochondria in metabolism

Cheng, Z., Tseng, Y. D., & White, M. F. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.06.005 · Cited by 450 · see citing works

Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

Liu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439 · see citing works

Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling

Kickstein, E., Krauß, S., Thornhill, P., Rutschow, D., Zeller, R., Sharkey, J., Williamson, R., Fuchs, M., Köhler, A., Glossmann, H. H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912793107 · Cited by 432 · see citing works

Differential Expression of Oxidative Phosphorylation Genes in Patients With Alzheimer's Disease: Implications for Early Mitochondrial Dysfunction and Oxidative Damage

Mańczak, M., Park, B. S., Jung, Y., & Reddy, P. H. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:2:147 · Cited by 432 · see citing works

DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism

Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., Swieten, J. C. V., Brice, A., van Duijn, C. M., Oostra, B. A., Meco, G., et al. (2003) · Neurological Sciences · doi:10.1007/s10072-003-0108-0 · Cited by 427 · see citing works

Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin

Moore, E. M., Mander, A. G., Ames, D. J., Kotowicz, M. A., Carne, R. P., Brodaty, H., Woodward, M., Boundy, K. L., Ellis, K. A., Bush, A. I., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0229 · Cited by 405 · see citing works

Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications.

Nishikawa, T., & Araki, E. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.1458 · Cited by 391 · see citing works

Antidiabetic drug metformin (Glucophage ^R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating <i>BACE1</i> transcription

Chen, Y., Zhou, K., Wang, R., Liu, Y., Kwak, Y.-D., Ma, T., Thompson, R. C., Zhao, Y., Smith, L., Gasparini, L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807991106 · Cited by 390 · see citing works

Metformin, Other Antidiabetic Drugs, and Risk of Alzheimer's Disease: A Population‐Based Case–Control Study

Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03916.x · Cited by 389 · see citing works

Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease

Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387 · see citing works

Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein

Grünblatt, E., Šalković‐Petrišić, M., Barilar, J. O., Riederer, P. F., & Hoyer, S. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04368.x · Cited by 376 · see citing works

Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease

Breidert, T., Callebert, J., Heneka, M. T., Landreth, G. E., Launay, J., & Hirsch, É. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00990.x · Cited by 375 · see citing works

Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice

Ou, Z., Kong, X., Sun, X., He, X., Zhang, L., Gong, Z., Huang, J., Xu, B., Long, D., Li, J., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.12.009 · Cited by 370 · see citing works

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · see citing works

Effects of the Insulin Sensitizer Metformin in Alzheimer Disease

Koenig, A. M., Mechanic-Hamilton, D. J., Xie, S. X., Combs, M., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000202 · Cited by 352 · see citing works

Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer’s disease

Manczak, M., & Reddy, P. H. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds360 · Cited by 348 · see citing works

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., & Hampel, H. J. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.005 · Cited by 345 · see citing works

Effects of Regular and Long-Acting Insulin on Cognition and Alzheimer’s Disease Biomarkers: A Pilot Clinical Trial

Craft, S., Claxton, A., Baker, L. D., Hanson, A. J., Cholerton, B., Trittschuh, E. H., Dahl, D., Caulder, E., Neth, B., Montine, T. J., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161256 · Cited by 335 · see citing works

Long-Term Metformin Usage and Cognitive Function among Older Adults with Diabetes

Ng, T. P., Feng, L., Yap, K. B., Lee, T. S., Tan, C. H., & Winblad, B. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131901 · Cited by 334 · see citing works

Insulin resistance and Parkinson’s disease: A new target for disease modification?

Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 333 · see citing works

Insulin Resistance and Neurodegeneration: Progress towards the Development of New Therapeutics for Alzheimer's Disease

de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331 · see citing works

The Therapeutic Potential of Metformin in Neurodegenerative Diseases

Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 310 · see citing works

Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer’s-like changes

Gupta, A., Bisht, B., & Dey, C. S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.033 · Cited by 302 · see citing works

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286 · see citing works

Neuroprotective effect of metformin in MPTP-induced Parkinson’s disease in mice

Patil, S. P., Jain, P. D., Ghumatkar, P. J., Tambe, R., & Sathaye, S. S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.046 · Cited by 273 · see citing works

Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice

Li, J., Deng, J., Sheng, W., & Zuo, Z. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.03.002 · Cited by 260 · see citing works

Insulin dose–response effects on memory and plasma amyloid precursor protein in Alzheimer’s disease: interactions with apolipoprotein E genotype

Craft, S., Asthana, S., Cook, D. G., Baker, L. D., Cherrier, M. M., Purganan, K., Wait, C., Petrova, A., Latendresse, S. J., Watson, G. S., et al. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00087-2 · Cited by 255 · see citing works

Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease

Dolgacheva, L. P., Berezhnov, A. V., Fedotova, E. I., Zinchenko, V. P., & Abramov, A. Y. (2019) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-019-09798-4 · Cited by 254 · see citing works

Modifiable Risk Factors for Alzheimer’s Disease

Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253 · see citing works

Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson’s Disease via Autophagy and Mitochondrial ROS Clearance

Lu, M., Su, C., Qiao, C., Bian, Y., Ding, J., & Hu, G. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw047 · Cited by 252 · see citing works

Metformin – a Future Therapy for Neurodegenerative Diseases

Markowicz-Piasecka, M., Sikora, J., Szydłowska, A., Skupień, A., Mikiciuk-Olasik, E., & Huttunen, K. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2199-y · Cited by 248 · see citing works

Diabetes and Risk of Parkinson’s Disease

Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., & Pezzoli, G. (2011) · Diabetes Care · doi:10.2337/dc11-1584 · Cited by 247 · see citing works

Nitrosamine Exposure Causes Insulin Resistance Diseases: Relevance to Type 2 Diabetes Mellitus, Non-Alcoholic Steatohepatitis, and Alzheimer's Disease

Tong, M., Neusner, A. D., Longato, L., Lawton, M., Wands, J. R., & de la Monte, S. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1115 · Cited by 247 · see citing works

The Relationship Between Diabetes Mellitus and Parkinson'S Disease

Sandyk, R. (1993) · International Journal of Neuroscience · doi:10.3109/00207459309003322 · Cited by 244 · see citing works

Diabetes mellitus and Parkinson disease

Pagano, G., Polychronis, S., Wilson, H., Giordano, B., Ferrara, N., Niccolini, F., & Politis, M. (2018) · Neurology · doi:10.1212/wnl.0000000000005475 · Cited by 243 · see citing works

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study

De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T. (2018) · Neurology · doi:10.1212/wnl.0000000000005771 · Cited by 242 · see citing works

Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease

Dunn, L., Allen, G. F. G., Mamais, A., Ling, H., Li, A., Duberley, K. E. C., Hargreaves, I. P., Pope, S. A. S., Holton, J. L., Lees, A. J., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.11.001 · Cited by 241 · see citing works

Rosiglitazone rescues memory impairment in Alzheimer’s transgenic mice: Mechanisms involving a reduced amyloid and tau pathology

Escribano, L., Simón, A.-M., Gimeno, E., Cuadrado-Tejedor, M., López de Maturana, R., García-Osta, A., Ricobaraza, A., Pérez-Mediavilla, A., Del Río, J., & Frechilla, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.32 · Cited by 235 · see citing works

Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort

Wahlqvist, M. L., Lee, M., Hsu, C.-C., Chuang, S., Lee, J.-T., & Tsai, H.-N. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.03.010 · Cited by 233 · see citing works

The future of Alzheimer's disease: The next 10 years

Hampel, H. J., Prvulovic, D., Teipel, S. J., Jessen, F., Luckhaus, C., Frölich, L., Riepe, M. W., Dodel, R. C., Leyhe, T., Bertram, L., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.008 · Cited by 233 · see citing works

RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation

Malagelada, C., Jin, Z. H., & Greene, L. A. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3928-08.2008 · Cited by 228 · see citing works

Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus

Guo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12265 · Cited by 225 · see citing works

Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic β-cell function in diabetes

Hoshino, A., Ariyoshi, M., Okawa, Y., Kaimoto, S., Uchihashi, M., Fukai, K., Iwai‐Kanai, E., Ikeda, K., Ueyama, T., Ogata, T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318951111 · Cited by 221 · see citing works

A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease

Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221 · see citing works

PPAR‐gamma‐mediated neuroprotection in a chronic mouse model of Parkinson’s disease

Schintu, N., Frau, L., Ibba, M., Caboni, P., Garau, A., Carboni, E., & Carta, A. R. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06657.x · Cited by 200 · see citing works

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Harrington, C. M., Sawchak, S. T., Chiang, C., Davies, J., Donovan, C., Saunders, A. M., Irizarry, M. C., Jeter, B., Zvartau-Hind, M. E., van Dyck, C. H., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 198 · see citing works

Risk of Parkinson Disease in Diabetes Mellitus

Yue, X., Li, H., Yan, H., Zhang, P., Li, C., & Li, T. (2016) · Medicine · doi:10.1097/md.0000000000003549 · Cited by 188 · see citing works

Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra

Figlewicz, D. P., Szot, P., Chavez, M., Woods, S. C., & Veith, R. C. (1994) · Brain Research · doi:10.1016/0006-8993(94)91698-5 · Cited by 172 · see citing works

Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease

Xu, Y., Liu, C., Chen, S., Ye, Y., Guo, M., Ren, Q., Liu, L., Zhang, H., Xu, C., Zhou, Q., et al. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.04.009 · Cited by 171 · see citing works

Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis

Cheng, C., Lin, C.-H., Tsai, Y.-W., Tsai, C.-J., Chou, P.-H., & Lan, T.-H. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu073 · Cited by 167 · see citing works

Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet

Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163 · see citing works

Effect of Intranasal Insulin on Cognitive Function: A Systematic Review

Shemesh, E., Rudich, A., Harman-Boehm, I., & Cukierman-Yaffe, T. (2012) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2011-1802 · Cited by 162 · see citing works

Long-Term Pioglitazone Treatment Improves Learning and Attenuates Pathological Markers in a Mouse Model of Alzheimer's Disease

Searcy, J. L., Phelps, J. T., Pancani, T., Kadish, I., Popovic, J., Anderson, K. L., Beckett, T. L., Murphy, M. P., Chen, K.-C., Blalock, E. M., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111661 · Cited by 154 · see citing works

Metabolic Alterations Induced by Sucrose Intake and Alzheimer’s Disease Promote Similar Brain Mitochondrial Abnormalities

Carvalho, C., Cardoso, S., Correia, S. C., Santos, R. X., Santos, M. S., Baldeiras, I., Oliveira, C. R., & Moreira, P. I. (2012) · Diabetes · doi:10.2337/db11-1186 · Cited by 152 · see citing works

Insulin resistance impairs nigrostriatal dopamine function

Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 150 · see citing works

Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease

Moroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P., Mcgeer, E., & Hirayama, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00313602 · Cited by 149 · see citing works

Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation

Pérez‐Revuelta, B. I., Hettich, M. M., Ciociaro, A., Rotermund, C., Kahle, P. J., Krauß, S., & Monte, D. A. D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.175 · Cited by 146 · see citing works

Alzheimer’s disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers

Carvalho, C., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.001 · Cited by 145 · see citing works

p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease.

Jha, S. K., Jha, N. K., Kar, R., Ambasta, R. K., & Kumar, P. (2015) · Europe PMC (PubMed Central) · Cited by 143 · see citing works

Dopaminergic pathway reconstruction by Akt/Rheb‐induced axon regeneration

Kim, S. R., Chen, X. M., Oo, T. F., Kareva, T., Yarygina, O., Wang, C., During, M. J., Kholodilov, N. G., & Burke, R. E. (2011) · Annals of Neurology · doi:10.1002/ana.22383 · Cited by 143 · see citing works

Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model

Guo, Z., Chen, Y., Mao, Y., Zheng, T., Jiang, Y., Yan, Y., Yin, X., & Zhang, B. (2017) · Scientific Reports · doi:10.1038/srep45971 · Cited by 143 · see citing works

Intranasal insulin in Alzheimer’s dementia or mild cognitive impairment: a systematic review

Avgerinos, K. I., Kalaitzidis, G., Malli, A., Kalaitzoglou, D., Myserlis, E. P., & Lioutas, V. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8768-0 · Cited by 137 · see citing works

Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model

Carta, A. R., Frau, L., Pisanu, A., Wardas, J., Spiga, S., & Carboni, E. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.07.046 · Cited by 136 · see citing works

Late-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles

Sonntag, K.-C., Ryu, W.-I., Amirault, K. M., Healy, R. A., Siegel, A. J., McPhie, D. L., Forester, B., & Cohen, B. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14420-x · Cited by 131 · see citing works

Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance

Chen, J., Luo, C., Pu, D., Zhang, G., Zhao, Y., Sun, Y., Zhao, K., Liao, Z., Lv, A., Zhu, S., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.008 · Cited by 131 · see citing works

Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study

Novák, P., Maldonado, D. P., & Novak, V. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214364 · Cited by 131 · see citing works

Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Aβ level and microglia activation in the brains of 3xTg-AD mice

Chen, Y., Yang, Z., Dai, C., Liang, Z., Run, X., Iqbal, K., Liu, F., & Gong, C. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.004 · Cited by 125 · see citing works

Glitazone Treatment and Incidence of Parkinson’s Disease among People with Diabetes: A Retrospective Cohort Study

Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D. T., Smeeth, L. L., & Douglas, I. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001854 · Cited by 124 · see citing works

Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction

Chiang, M., Cheng, Y., Chen, S., Yen, C., & Huang, R. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.08.013 · Cited by 123 · see citing works

Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt

Xing, B., Xin, T., Hunter, R. L., & Bing, G. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-4 · Cited by 122 · see citing works

Insulin Resistance Predicts Medial Temporal Hypermetabolism in Mild Cognitive Impairment Conversion to Alzheimer Disease

Willette, A. A., Modanlo, N., Kapogiannis, D., & Initiative, A. D. N. (2015) · Diabetes · doi:10.2337/db14-1507 · Cited by 118 · see citing works

Mitochondrial Abnormalities in a Streptozotocin-Induced Rat Model of Sporadic Alzheimer's Disease

Correia, S. C., Santos, R. X., Santos, M. S., Casadesús, G., LaManna, J. C., Perry, G. L., Smith, M. A., & Moreira, P. I. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310040006 · Cited by 116 · see citing works

Emerging neuroprotective effect of metformin in Parkinson’s disease: A molecular crosstalk

Paudel, Y. N., Angelopoulou, E., Piperi, C., Shaikh, M. F., & Othman, I. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104593 · Cited by 116 · see citing works

Alzheimer's disease: The next frontier—Special Report 2017

Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 114 · see citing works

O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-β precursor protein (APP)

Jacobsen, K. T., & Iverfeldt, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.080 · Cited by 113 · see citing works

Cognitive Enhancement with Rosiglitazone Links the Hippocampal PPARγ and ERK MAPK Signaling Pathways

Denner, L. A., Rodriguez-Rivera, J., Haidacher, S. J., Jahrling, J. B., Carmical, J. R., Hernandez, C. M., Zhao, Y., Sadygov, R. G., Starkey, J. M., Spratt, H. M., et al. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2153-12.2012 · Cited by 111 · see citing works

Mitochondrial function in Parkinson’s disease cybrids containing an nt2 neuron-like nuclear background

Esteves, A. R., Domingues, A. F., Ferreira, I. L., Januário, C., Swerdlow, R. H., Oliveira, C. R., & Cardoso, S. M. (2008) · Mitochondrion · doi:10.1016/j.mito.2008.03.004 · Cited by 110 · see citing works

The Pathogenesis of Alzheimer′s Disease: A Reevaluation of the “Amyloid Cascade Hypothesis”

Armstrong, R. A. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/630865 · Cited by 109 · see citing works

A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease

Tzimopoulou, S., Cunningham, V. J., Nichols, T. E., Searle, G. E., Bird, N., Mistry, P. C., Dixon, I. J., Hallett, W. A., Whitcher, B. J., Brown, A. P., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100939 · Cited by 108 · see citing works

Glitazone use associated with reduced risk of Parkinson's disease

Brakedal, B., Flønes, I. H., Reiter, S. F., Torkildsen, Ø., Dölle, C., Aßmus, J., Haugarvoll, K., & Tzoulis, C. (2017) · Movement Disorders · doi:10.1002/mds.27128 · Cited by 108 · see citing works

Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: roles of aging, superoxide, NADPH oxidase, and p38 MAPK

Wang, X.-J., Zhang, S., Yan, Z.-Q., Zhao, Y.-X., Zhou, H.-Y., Wang, Y., Lu, G.-Q., & Zhang, J.-D. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.01.032 · Cited by 108 · see citing works

Alzheimer’s Disease and Diabetes: Insulin Signaling as the Bridge Linking Two Pathologies

Shieh, J. C.-C., Huang, P.-T., & Lin, Y. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01858-5 · Cited by 104 · see citing works

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production

Jung, T. W., Lee, J. Y., Shim, W. S., Kang, E. S., Kim, S. K., Ahn, C. W., Lee, H. C., & Soo, B. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.11.020 · Cited by 103 · see citing works

Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm

Barone, E., Di Domenico, F., Cassano, T., Arena, A., Tramutola, A., Lavecchia, M. A., Coccia, R., Butterfield, D. A., & Perluigi, M. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.12.012 · Cited by 100 · see citing works

Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats

Pang, Y., Lin, S., Wright, C., Shen, J., Carter, K., Bhatt, A., & Fan, L.-W. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.01.020 · Cited by 99 · see citing works

Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.

Alagiakrishnan, K., Sankaralingam, S., Ghosh, M., Mereu, L., & Senior, P. A. (2013) · PubMed · Cited by 98 · see citing works

Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes

Jain, D., Jain, R., Eberhard, D., Eglinger, J., Bugliani, M., Piemonti, L., Marchetti, P., & Lammert, E. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs025 · Cited by 98 · see citing works

Metformin and the Risk of Dementia in Type 2 Diabetes Patients

Chin-Hsiao, T. (2018) · Aging and Disease · doi:10.14336/ad.2017.1202 · Cited by 98 · see citing works

Intranasal Insulin Administration Ameliorates Streptozotocin (ICV)-Induced Insulin Receptor Dysfunction, Neuroinflammation, Amyloidogenesis, and Memory Impairment in Rats

Rajasekar, N., Nath, C., Hanif, K., & Shukla, R. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0169-8 · Cited by 94 · see citing works

Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice

Khang, R., Park, C., & Shin, J.-H. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.017 · Cited by 93 · see citing works

Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease – How Anti-Diabetics Could be a Solution for Dementia

Sebastião, I., Candeias, E., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00110 · Cited by 92 · see citing works

Long Acting Intranasal Insulin Detemir Improves Cognition for Adults with Mild Cognitive Impairment or Early-Stage Alzhemir's Disease Dementia

(2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-159002 · Cited by 87 · see citing works

Type 2 Diabetic and Alzheimer's Disease Mice Present Similar Behavioral, Cognitive, and Vascular Anomalies

Carvalho, C., Machado, N. J., Mota, P. C., Correia, S. C., Cardoso, S., Santos, R. X., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130005 · Cited by 85 · see citing works

Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences

Sergi, D., Renaud, J., Simola, N., & Martinoli, M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00302 · Cited by 85 · see citing works

The impairment of insulin signaling in Alzheimer's disease

Candeias, E., Duarte, A. I., Carvalho, C., Correia, S. C., Cardoso, S., Santos, R. X., Plácido, A. I., Perry, G. L., & Moreira, P. I. (2012) · IUBMB Life · doi:10.1002/iub.1098 · Cited by 79 · see citing works

Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes

Santiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 78 · see citing works

Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation

Pinto, M., Nissanka, N., Peralta, S., Brambilla, R., Díaz, F., & Moraes, C. T. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0090-7 · Cited by 77 · see citing works

Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of View

Biosa, A., Outeiro, T. F., Bubacco, L., & Bisaglia, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1025-9 · Cited by 74 · see citing works

Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies

Pinho, T. S., Correia, S. C., Perry, G., Ambrósio, A. F., & Moreira, P. I. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.037 · Cited by 70 · see citing works

Neuroprotective effect of metformin on dopaminergic neurodegeneration and α-synuclein aggregation in C. elegans model of Parkinson’s disease

Saewanee, N., Praputpittaya, T., Malaiwong, N., Chalorak, P., & Meemon, K. (2019) · Neuroscience Research · doi:10.1016/j.neures.2019.12.017 · Cited by 68 · see citing works

PROGRESSION AND PROGNOSIS IN PARKINSONʼS DISEASE

Schwab, R. S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196006000-00017 · Cited by 66 · see citing works

Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes

Cheng, H., Gang, X., Liu, Y., Wang, G., Zhao, X., & Wang, G. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2019 · Cited by 62 · see citing works

Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice

Yu, Y., Li, X., Blanchard, J., Li, Y., Iqbal, K., Liu, F., & Gong, C. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1294-z · Cited by 58 · see citing works

Rapid transport of insulin to the brain following intranasal administration in rats

Fan, L.-W., Carter, K., Bhatt, A., & Pang, Y. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.250624 · Cited by 58 · see citing works

Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson’s Disease

Fine, J. M., STROEBEL, B. M., Faltesek, K. A., Terai, K., Haase, L. R., Knutzen, K. E., Kosyakovsky, J., Bowe, T. J., Fuller, A. K., Frey, W. H., et al. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134567 · Cited by 52 · see citing works

The Neuroprotective Role of Insulin Against MPP+‐Induced Parkinson's Disease in Differentiated SH‐SY5Y Cells

Ramalingam, M., & Kim, S. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25376 · Cited by 51 · see citing works

Metformin beyond diabetes: new life for an old drug.

Rotella, C., Monami, M., & Mannucci, E. (2006) · Current Diabetes Reviews · doi:10.2174/157339906777950651 · Cited by 50 · see citing works

Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer’s Rat Model

Chen, Y., Guo, Z., Mao, Y., Zheng, T., & Zhang, B. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9809-7 · Cited by 48 · see citing works

PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice

Deas, E., Piipari, K., Machhada, A., Li, A., del Arroyo, A. G., Withers, D. J., Wood, N. W., & Abramov, A. Y. (2014) · Open Biology · doi:10.1098/rsob.140051 · Cited by 46 · see citing works

Diabetes and neurodegeneration in the brain

Toth, C. C. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53480-4.00035-7 · Cited by 46 · see citing works

Glucose metabolism in small subcortical structures in Parkinson’s disease

Borghammer, P., Hansen, S. B., Eggers, C., Chakravarty, M. M., Vang, K., Aanerud, J., Hilker, R., Heiss, W., Rodell, A. B., Munk, O. L., et al. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01556.x · Cited by 44 · see citing works

Effects of Pioglitazone or Exercise in Older Adults with Mild Cognitive Impairment and Insulin Resistance: A Pilot Study

Hildreth, K. L., Pelt, R. E. V., Moreau, K. L., Grigsby, J., Hoth, K. F., Pelak, V. S., Anderson, C. A., Parnes, B. L., Kittelson, J. M., Wolfe, P., et al. (2015) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000371509 · Cited by 44 · see citing works

Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity

Jung, T. W., Lee, J. Y., Shim, W. S., Kang, E. S., Kim, S. K., Ahn, C. W., Lee, H. C., & Soo, B. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.177 · Cited by 43 · see citing works

Thiazolidinediones and Parkinson Disease: A Cohort Study

Connolly, J. G., Bykov, K., & Gagne, J. J. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv109 · Cited by 39 · see citing works

O-GlcNAcylation and neuronal energy status: Implications for Alzheimer’s disease

Pinho, T. S., Verde, D. V., Correia, S. C., Cardoso, S., & Moreira, P. I. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.003 · Cited by 38 · see citing works

Genetic suppression of IKK2/NF-κB in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-Probenecid model of Parkinson's disease

Kirkley, K. S., Popichak, K. A., Hammond, S. L., Davies, C., Hunt, L. G., & Tjalkens, R. B. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.020 · Cited by 37 · see citing works

Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson’s disease

Carta, A. R., & Simuni, T. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.963195 · Cited by 36 · see citing works

High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats

Sharma, S., & Taliyan, R. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.025 · Cited by 36 · see citing works

Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP/PS1 Alzheimer model mice

Gabbouj, S., Natunen, T., Koivisto, H., Jokivarsi, K. T., Takalo, M., Marttinen, M., Wittrahm, R., Kemppainen, S., Naderi, R., Posado-Fernández, A., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.11.008 · Cited by 34 · see citing works

Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer’s disease

Jojo, G. M., & Kuppusamy, G. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12808 · Cited by 34 · see citing works

US government sets out Alzheimer’s plan

Wadman, M. (2012) · Nature · doi:10.1038/485426a · Cited by 33 · see citing works

Pioglitazone use and Parkinson’s disease: a retrospective cohort study in Taiwan

Wu, H.-F., Kao, L., Shih, J., Kao, H., Chou, Y., Li, I., & Kao, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023302 · Cited by 30 · see citing works

Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 2013;36:2981–2987

Moore, E., Mander, A. G., Ames, D. J., Kotowicz, M. A., Carne, R., Brodaty, H., Woodward, M., Boundy, K., Ellis, K. A., Bush, A. I., et al. (2013) · Diabetes Care · doi:10.2337/dc13-er11b · Cited by 29 · see citing works

Management of type 2 diabetes mellitus. Role of thiazolidinediones.

Noble, J., Baerlocher, M. O., & Silverberg, J. (2005) · Europe PMC (PubMed Central) · Cited by 25 · see citing works

Rosiglitazone Improves Learning and Memory Ability in Rats With Type 2 Diabetes Through the Insulin Signaling Pathway

Ma, L., Shao, Z., Wang, R., Zhao, Z., Dong, W., Zhang, J., Zhang, X., Sheng, S., Ji, Z., & Zhang, J. (2015) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000499 · Cited by 25 · see citing works

Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients

Tseng, C. (2019) · Aging · doi:10.18632/aging.101944 · Cited by 25 · see citing works

A shared comparison of diabetes mellitus and neurodegenerative disorders

Morsi, M., Kobeissy, F. H., Magdeldin, S., Maher, A., Aboelmagd, O., Johar, D., & Bernstein, L. H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28094 · Cited by 24 · see citing works

Diabesity and Brain Energy Metabolism: The Case of Alzheimer’s Disease

Cardoso, S., Seiça, R. M. F., & Moreira, P. I. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-63260-5_5 · Cited by 22 · see citing works

Could α-Synuclein Modulation of Insulin and Dopamine Identify a Novel Link Between Parkinson’s Disease and Diabetes as Well as Potential Therapies?

Vidal-Martínez, G., Yang, B. C., Vargas‐Medrano, J., & Perez, R. G. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00465 · Cited by 15 · see citing works

Protective effects of activated signaling pathways by insulin on C6 glial cell model of MPP+-induced Parkinson’s disease

Ramalingam, M., & Kim, S.-J. (2016) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2016.1171342 · Cited by 14 · see citing works

Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981–2987

Goodarzi, M. O. (2014) · Diabetes Care · doi:10.2337/dc13-2473 · Cited by 5 · see citing works

Thioredoxin-Interacting Protein (TXNIP) with Focus on Brain and Neurodegenerative Diseases

Tsubaki, H., Tooyama, I., & Walker, D. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249357 · Cited by 145 · see citing works

The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson's disease

Li, H., Zeng, F., Huang, C., Pu, Q., Thomas, E. R., Chen, Y., & Li, X. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14411 · Cited by 45 · see citing works

Diabetes medications as potential calorie restriction mimetics—a focus on the alpha-glucosidase inhibitor acarbose

Smith, D. L., Orlandella, R. M., Allison, D. B., & Norian, L. A. (2020) · GeroScience · doi:10.1007/s11357-020-00278-x · Cited by 43 · see citing works

DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson’s disease: a mutual relationship

Alrouji, M., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Elekhnawy, E., & Batiha, G. E. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00500-5 · Cited by 40 · see citing works

Pesticides and the Microbiome-Gut-Brain Axis: Convergent Pathways in the Pathogenesis of Parkinson’s Disease

Kulcsarova, K., Bang, C., Berg, D., & Schaeffer, E. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-230206 · Cited by 40 · see citing works

Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer’s Disease Treatment

Poor, S. R., Ettcheto, M., Cano, A. C., Sánchez‐López, E., Manzine, P. R., Olloquequi, J., Camins, A., & Javan, M. (2021) · Pharmaceuticals · doi:10.3390/ph14090890 · Cited by 40 · see citing works

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents

Dhas, Y., Biswas, N., Divyalakshmi, M. R., Jones, L., & Ashili, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00204-z · Cited by 38 · see citing works

Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders

Birajdar, S. V., Mazahir, F., Alam, M. I., Kumar, A., & Yadav, A. K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176117 · Cited by 36 · see citing works

The gut–brain axis in early Parkinson’s disease: from prodrome to prevention

Oliver, P. J., Civitelli, L., & Hu, M. T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13138-5 · Cited by 42 · see citing works

Repositioning of Anti-Diabetic Drugs against Dementia: Insight from Molecular Perspectives to Clinical Trials

Mantik, K. E. K., Kim, S., Gu, B., Moon, S., Kwak, H., Park, D., & Kang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411450 · Cited by 35 · see citing works

An Update on the Potential of Tangeretin in the Management of Neuroinflammation-Mediated Neurodegenerative Disorders

Wani, I., Koppula, S., Balda, A., Thekkekkara, D., Jamadagni, A., Walse, P., Manjula, S. N., & Kopalli, S. R. (2024) · Life · doi:10.3390/life14040504 · Cited by 26 · see citing works

Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson’s Disease Rat Model

Delvadia, P., Dhote, V. V., Mandloi, A. S., Soni, R., & Shah, J. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00729 · Cited by 25 · see citing works

Repurposing old molecules for new indications: Defining pillars of success from lessons in the past

Mittal, N., & Mittal, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174569 · Cited by 25 · see citing works

Thiazolidinedione use and risk of Parkinson’s disease in patients with type 2 diabetes mellitus

Zhao, H.-Y., Zhuo, L., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00406-8 · Cited by 25 · see citing works

Thiazolidinedione use is associated with reduced risk of dementia in patients with type 2 diabetes mellitus: A retrospective cohort study

Zhao, H.-Y., Zhuo, L., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13352 · Cited by 25 · see citing works

Conquering Insulin Network Dysfunctions in Alzheimer’s Disease: Where Are We Today?

de la Monte, S. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240069 · Cited by 24 · see citing works

Brain-specific targeted delivery of therapeutic agents using metal–organic framework-based nanomedicine

Han, Z., Yuan, M., Nguyen, N., Zhou, H.-C. “., Hubbard, J. E., & Wang, Y. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215926 · Cited by 23 · see citing works

Actions and Consequences of Insulin in the Striatum

Patel, J. C., Carr, K. D., & Rice, M. E. (2023) · Biomolecules · doi:10.3390/biom13030518 · Cited by 23 · see citing works

Metformin Enhances Excitatory Synaptic Transmission onto Hippocampal CA1 Pyramidal Neurons

Chen, W., Chen, J., Liu, Z., Luo, B., Zhou, T. G., & Fei, E. (2020) · Brain Sciences · doi:10.3390/brainsci10100706 · Cited by 22 · see citing works

A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress

Li, S., Liu, Y., Lu, S., Xu, J., Liu, X., Yang, D., Yang, Y., Hou, L., & Li, N. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04985-3 · Cited by 21 · see citing works

Therapeutic drug monitoring in Parkinson’s disease

Müller, T. H., Gerlach, M., Hefner, G., Hiemke, C., Jost, W. H., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02828-5 · Cited by 23 · see citing works

Onset and mortality of Parkinson’s disease in relation to type II diabetes

Pezzoli, G., Cereda, E., Amami, P., Colosimo, S., Barichella, M., Sacilotto, G., Zecchinelli, A., Zini, M., Ferri, V., Bolliri, C., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11496-y · Cited by 21 · see citing works

Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs

Thomas, C., Wurzer, L., Malle, E., Ristow, M., & Madreiter‐Sokolowski, C. T. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.905261 · Cited by 18 · see citing works

Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches

Colca, J. R., & Finck, B. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.929328 · Cited by 16 · see citing works

Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial

Burns, J. M., Morris, J. K., Vidoni, E. D., Wilkins, H., Choi, I., Lee, P., Hunt, S. L., Mahnken, J. D., Brooks, W. M., Lepping, R. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70416 · Cited by 14 · see citing works

Status and future directions of clinical trials in Parkinson's disease

Söderbom, G. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.009 · Cited by 14 · see citing works

The impact of diabetes mellitus on the development of psychiatric and neurological disorders

Kelly, O., Sullivan, J., Carris, N., Geci, S., Martinez, A., Liashenko, V., Colvin, J., Misko, E., Vanderlaan, G., He, L., et al. (2024) · Brain Disorders · doi:10.1016/j.dscb.2024.100135 · Cited by 16 · see citing works

Post-Treatment with Amorfrutin B Evokes PPARγ-Mediated Neuroprotection against Hypoxia and Ischemia

Wnuk, A., Przepiórska, K., Pietrzak, B. A., & Kajta, M. (2021) · Biomedicines · doi:10.3390/biomedicines9080854 · Cited by 13 · see citing works

Gut Microbiota: A Key Regulator in the Effects of Environmental Hazards on Modulates Insulin Resistance

Huang, R. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.800432 · Cited by 13 · see citing works

Metformin use and brain atrophy in nondemented elderly individuals with diabetes

Nabizadeh, F., Kankam, S. B., Balabandian, M., Hashemi, S. M., Sharifkazemi, H., & Rostami, M. R. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111890 · Cited by 12 · see citing works

Hyperglycemia-Driven Insulin Signaling Defects Promote Parkinson’s Disease-like Pathology in Mice

Soni, R., Mathur, K., Rathod, H., Khairnar, A., & Shah, J. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00586 · Cited by 9 · see citing works

Intranasal Administration of Forskolin and Noopept Reverses Parkinsonian Pathology in PINK1 Knockout Rats

Dagda, R. K., Dagda, R. Y., Vazquez‐Mayorga, E., Martinez, B., & Gallahue, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010690 · Cited by 9 · see citing works

Progress in anti-ageing drug research for age-related diseases: A review

Zhou, Z., Duan, H.-T., Xue, S.-T., & Li, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102982 · Cited by 7 · see citing works

Association study between drug prescriptions and Alzheimer’s disease claims in a commercial insurance database

Hu, E., Li, T. S., Wineinger, N. E., & Su, A. I. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01255-0 · Cited by 9 · see citing works

Metformin Ameliorates Postoperative Cognitive Dysfunction through Regulation of the AMPK/SIRT1 Pathway

Jia, P., Che, J., Zhang, J., Li, H., Zhou, Q., & Guo, Y. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205110 · Cited by 7 · see citing works

Targeting neuroendocrine abnormalities in Parkinson’s disease with exercise

Luthra, N., Christou, D. D., Clow, A., & Corcos, D. M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1228444 · Cited by 7 · see citing works

Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment

Duţă, C., Muscurel, C., Dogaru, C. B., & Stoian, I. A.-M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041516 · Cited by 7 · see citing works

The Effects of Combined Therapy With Metformin and Hydroxypropyl-β-Cyclodextrin in a Mouse Model of Niemann-Pick Disease Type C1

Du, J., Liu, X., Zhang, Y., Han, X., Ma, C., Liu, Y., Guan, L., Qiao, L., & Lin, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.825425 · Cited by 6 · see citing works

Impaired Gonadotropin-Lowering Effects of Metformin in Postmenopausal Women with Autoimmune Thyroiditis: A Pilot Study

Krysiak, R. G., Basiak, M., Machnik, G., & Okopień, B. (2023) · Pharmaceuticals · doi:10.3390/ph16070922 · Cited by 6 · see citing works

Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson's disease

Pezzoli, G., Cereda, E., Calandrella, D., Barichella, M., Bonvegna, S., & Isaias, I. U. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.02.018 · Cited by 6 · see citing works

The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials

Sobral, M. V. S., Soares, V. G., Moreira, J. L. D. M. L., Rodrigues, L. K., Rocha, P., Bendaham, L. C. A. R., Gonçalves, O. R., Pirolla, R. D. C., Vilela, L. V., de Abreu, V. S., et al. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107210 · Cited by 6 · see citing works

Snapshot of disease continuum centered on Alzheimer's disease: Exploring modifiable risk factors

Zheng, M. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111316 · Cited by 5 · see citing works

Pathophysiological mechanisms linking osteoarthritis and neurodegenerative disease risk

Prasoon, P., Nguyen, K. L., Fathi, P. A., Gupta, S., Arnab, S., Jones, E. C., Meyyappan, A., Stehle, E. J., & Bethea, J. R. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.10.009 · Cited by 4 · see citing works

Relationship between Parkinson's disease and diabetes mellitus: Evidence from the bench to bedside

Peng, Y., Lin, L.-Y., Wu, S.-L., Kang, X.-H., Jiang, D., Yao, S., & Du, M. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.108109 · Cited by 4 · see citing works

Analysis of current situation and influencing factors of cognitive dysfunction associated with type 2 diabetes and follow-up study on treatment effectiveness

Liu, M., Wang, Z., Han, J., Mu, Z., & Bian, H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1419017 · Cited by 4 · see citing works

Subclinical Hyperthyroidism Enhances Gonadotropin‐Lowering Effects of Metformin in Postmenopausal Women

Krysiak, R. G., Kowalcze, K. E., & Okopień, B. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6144 · Cited by 4 · see citing works

Modern Pharmacological Treatment of Parkinson's Disease : Reviving Known Drugs and New Perspectives

Lastovetskyi, I., Cytlau, B., Marczyk, Ł., Zdrojewska, K., Łach, A., Krupa, J. K., Lorkowska-Zawicka, B., & Bujak-Giżycka, B. (2024) · International Journal Of Pharmaceutical Research And Allied Sciences · doi:10.51847/twysubd6pp · Cited by 3 · see citing works

From Glucose to Neuroprotection: Exploring Antidiabetic Medications as a Novel Approach to Alzheimer's Disease Treatment

Pandiyan, C. K., Manivannan, A. G., Jaishankar, N., & Vellapandian, C. (2024) · Cureus · doi:10.7759/cureus.70710 · Cited by 2 · see citing works

A Growing Journey From Neurotrophins To Metabotrophins In Cardiometabolic Diseases

Aloe, L., Vinciguerra, M., Tonchev, A. B., Fiore, M., Deleva, N. S., Fröhlich, J., & Chaldakov, G. N. (2021) · Adipobiology · doi:10.14748/adipo.v11.8558 · Cited by 1 · see citing works

The role of mitochondrial dysfunction in diabetes-associated cognitive dysfunction: A bibliometric analysis

Wang, C., He, S., Wang, L., Yin, Y., Zhang, W., Lin, G., Wu, D., Zhou, Q., & Wang, Z. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251364845 · Cited by 1 · see citing works

Type 2 Diabetes Mellitus and Parkinson's Disease: An Emerging Link

Teli, S., Shalavadi, M. H., Mangannavar, C. V., & Anawal, L. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624334102241115162404 · Cited by 1 · see citing works

Revisiting Parkinson’s Disease Treatment: Exploring Established Medications and Emerging Therapies

Brooks, D., Carter, A., Moore, E., & Grant, O. (2024) · Journal of Applied Pharmaceutical Technologies and Systems · doi:10.68159/i340840675 · Cited by 1 · see citing works

Metabolic Disorder Therapeutics and their Effects on Memory

Aggarwal, P., Khan, M. F., & Banerjee, S. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273269329231013074613

CDC14 phosphatases control adipogenesis via PPARγ de-phosphorylationPreprint

Vara‐Ciruelos, D., Martins, A. F. B., Bakkali, A. E., Sánchez-Belmonte, A., Graña‐Castro, O., Zarzuela, E., Isasa, M., Salazar‐Roa, M., Villarroya‐Beltri, C., & Malumbres, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.13.694119

Additional file 3 of Association study between drug prescriptions and Alzheimer’s disease claims in a commercial insurance database

Hu, E. Y., Li, T. S., Wineinger, N. E., & Su, A. I. (2024) · Figshare · doi:10.6084/m9.figshare.26599405

Additional file 2 of Association study between drug prescriptions and Alzheimer’s disease claims in a commercial insurance database

Hu, E. Y., Li, T. S., Wineinger, N. E., & Su, A. I. (2024) · Figshare · doi:10.6084/m9.figshare.26599402

Additional file 1 of Association study between drug prescriptions and Alzheimer’s disease claims in a commercial insurance database

Hu, E. Y., Li, T. S., Wineinger, N. E., & Su, A. I. (2024) · Figshare · doi:10.6084/m9.figshare.26599399

Thiazolidinedione and reduced epilepsy risk: A population-based study using target trial emulation

Zhao, H., Zhuo, L., Zhang, B., Yin, Y., Sun, Y., Shen, P., Jiang, Z., & Zhan, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113184

Targeting Adult Neurogenesis in Prodromal Parkinson’s Disease Models: Pathological Insights and Therapeutic Opportunities

Bang, Y., Lee, S., Gal, J., & Choi, H. J. (2026) · Drug Targets and Therapeutics · doi:10.58502/dtt.25.0020

Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs

Goodarzi, G., Tehrani, S. S., Fana, S. E., Moradi‐Sardareh, H., Panahi, G., Maniati, M., & Meshkani, R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01225-3 · Cited by 28 · see citing works

Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease

Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179 · see citing works

Comprehending the Rationale for Repurposing Type 2 Diabetes Mellitus Medicines for Alzheimer's Disease Patients Via Gene Networks Studies and its Associated Molecular Pathways

Yadav, R., Mani, R. J., Kumar, A. H. S., Ahmad, S., & Katare, D. P. (2024) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2990 · Cited by 1 · see citing works

The role of antidiabetic drugs in the treatment of Alzheimer’s disease: systematic review

Ishmuratova, A. N., Abramov, M. A., Олегович, К. К., Ivanyuta, M. V., Shakirova, Z. F., Kitapova, A. I., Usmonov, M., Chernousova, L. M., Valeeva, L. I., Kuznetsova, A. Y., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13183 · Cited by 8 · see citing works

Alzheimer′s Disease and Type 2 Diabetes Mellitus: Risk Factors and Effectiveness of Antidiabetic Agents in Treatment of Alzheimer′s Disease

Myint, A. A. (2013) · Science Journal of Clinical Medicine · doi:10.11648/j.sjcm.20130203.20 · Cited by 6 · see citing works